[go: up one dir, main page]

MX2017001976A - Terapia de combinacion de anticuerpos activadores de la cd40 humana y anticuerpos contra el mp-l1 humano. - Google Patents

Terapia de combinacion de anticuerpos activadores de la cd40 humana y anticuerpos contra el mp-l1 humano.

Info

Publication number
MX2017001976A
MX2017001976A MX2017001976A MX2017001976A MX2017001976A MX 2017001976 A MX2017001976 A MX 2017001976A MX 2017001976 A MX2017001976 A MX 2017001976A MX 2017001976 A MX2017001976 A MX 2017001976A MX 2017001976 A MX2017001976 A MX 2017001976A
Authority
MX
Mexico
Prior art keywords
human
antibodies
combination therapy
activating
antibodies against
Prior art date
Application number
MX2017001976A
Other languages
English (en)
Inventor
Xu Wei
Stern Martin
OTT Marion
Levitsky Hyam
Gerdes Christian
Freytag Olivier
Rana Corse Emily
LE CLECH Marine
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15159611.1A external-priority patent/EP3070102A1/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2017001976A publication Critical patent/MX2017001976A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)

Abstract

La presente invencion se refiere a un producto farmaceutico para el tratamiento de una enfermedad proliferativa, que comprende la combinacion de un anticuerpo, o de una parte de union a antigeno del mismo, que se une especificamente a CD40 humano, y un anticuerpo de MP-L1, y opcionalmente un tercer componente que comprende a modo de ingrediente activo un inhibidor de citoquina.
MX2017001976A 2014-08-14 2015-08-11 Terapia de combinacion de anticuerpos activadores de la cd40 humana y anticuerpos contra el mp-l1 humano. MX2017001976A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14181067 2014-08-14
EP15159611.1A EP3070102A1 (en) 2015-03-18 2015-03-18 Combination therapy of antibodies human cd40 activating antibodies and anti human pld-1 antibodies
PCT/EP2015/068404 WO2016023875A1 (en) 2014-08-14 2015-08-11 Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1

Publications (1)

Publication Number Publication Date
MX2017001976A true MX2017001976A (es) 2017-08-02

Family

ID=53800992

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001976A MX2017001976A (es) 2014-08-14 2015-08-11 Terapia de combinacion de anticuerpos activadores de la cd40 humana y anticuerpos contra el mp-l1 humano.

Country Status (14)

Country Link
US (3) US20160045597A1 (es)
EP (2) EP3180357B1 (es)
JP (1) JP6586454B2 (es)
KR (1) KR20170035945A (es)
CN (1) CN106659780A (es)
AU (1) AU2015303239A1 (es)
BR (1) BR112016029334A2 (es)
CA (1) CA2949739A1 (es)
IL (1) IL249189A0 (es)
MX (1) MX2017001976A (es)
RU (1) RU2017108173A (es)
SG (1) SG11201701039PA (es)
TW (1) TW201609141A (es)
WO (1) WO2016023875A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4331604B9 (en) 2008-12-09 2025-07-23 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
SG11201707383PA (en) 2015-03-13 2017-10-30 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
US10696745B2 (en) 2015-06-11 2020-06-30 Wuxi Biologics (Shanghai) Co. Ltd. Anti-PD-L1 antibodies
WO2017020291A1 (en) 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
EP3400246B1 (en) 2016-01-08 2020-10-21 H. Hoffnabb-La Roche Ag Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
US10918737B2 (en) 2016-01-28 2021-02-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of cancer
SG11201810509PA (en) 2016-06-20 2018-12-28 Kymab Ltd Anti-pd-l1 antibodies
EP3606956B1 (en) 2017-04-04 2024-07-31 F. Hoffmann-La Roche AG Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
AU2018250875A1 (en) * 2017-04-13 2019-10-03 F. Hoffmann-La Roche Ag An interleukin-2 immunoconjugate, a CD40 agonist, and optionally a PD-1 axis binding antagonist for use in methods of treating cancer
LT3630143T (lt) * 2017-06-01 2023-09-25 Akamis Bio Limited Onkolitinis virusas ir būdas
US11168144B2 (en) 2017-06-01 2021-11-09 Cytomx Therapeutics, Inc. Activatable anti-PDL1 antibodies, and methods of use thereof
CA3086653A1 (en) * 2017-12-28 2019-07-04 Julius-Maximilians-Universitat Wurzburg Tumor necrosis factor (tnf) receptor superfamily (tnfrsf) receptor-activating antibody fusion proteins with fcyr-independent agonistic activity (tnfrsf receptor-activating antibody fusion proteins with fcyr-independ ent agonistic activity; traaffiaa)
CA3094500A1 (en) * 2018-03-23 2019-09-26 The University Of Western Australia Method for immunotherapy drug treatment
US20210147547A1 (en) * 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
US20210251994A1 (en) 2018-06-15 2021-08-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
BR112021008795A2 (pt) 2018-11-13 2021-08-31 Compass Therapeutics Llc Construtos de ligação multiespecíficos contra moléculas de ponto de verificação e seus usos
AR117091A1 (es) * 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
CN113677365A (zh) * 2019-01-22 2021-11-19 瑞伟生物科技公司(美国) 新型抗cd40抗体
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
US20240173442A1 (en) 2021-01-13 2024-05-30 Hoffmann-La Roche Inc. Combination therapy
JP2024512669A (ja) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
CA3224374A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024213533A1 (en) * 2023-04-13 2024-10-17 Alligator Bioscience Ab Combination therapies
WO2025185656A1 (zh) * 2024-03-06 2025-09-12 信达生物制药(苏州)有限公司 抗pd-l1和cd40双特异性抗体及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
CA2691357C (en) * 2007-06-18 2014-09-23 N.V. Organon Antibodies to human programmed death receptor pd-1
EP4331604B9 (en) * 2008-12-09 2025-07-23 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
KR20190133790A (ko) * 2011-08-01 2019-12-03 제넨테크, 인크. Pd-1 축 결합 길항제 및 mek 억제제를 사용하는 암 치료 방법
AU2013201121A1 (en) * 2011-09-20 2013-04-04 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease

Also Published As

Publication number Publication date
CA2949739A1 (en) 2016-02-18
IL249189A0 (en) 2017-01-31
EP3180357B1 (en) 2019-07-03
TW201609141A (zh) 2016-03-16
US20200095313A1 (en) 2020-03-26
JP6586454B2 (ja) 2019-10-02
WO2016023875A1 (en) 2016-02-18
KR20170035945A (ko) 2017-03-31
EP3180357A1 (en) 2017-06-21
EP3626740A1 (en) 2020-03-25
JP2017529327A (ja) 2017-10-05
SG11201701039PA (en) 2017-03-30
AU2015303239A1 (en) 2016-12-15
RU2017108173A3 (es) 2019-03-11
RU2017108173A (ru) 2018-09-17
BR112016029334A2 (pt) 2018-01-09
US20180051077A1 (en) 2018-02-22
US20160045597A1 (en) 2016-02-18
CN106659780A (zh) 2017-05-10

Similar Documents

Publication Publication Date Title
MX2017001976A (es) Terapia de combinacion de anticuerpos activadores de la cd40 humana y anticuerpos contra el mp-l1 humano.
IL267564A (en) Microbiota composition as a marker of antibody reactivity against pd1/pd-l1/pd-l2 and the use of microbial modulators to improve the efficacy of antibody-based therapy against pd1/pd-l1/pd-l2
MX2018005720A (es) Anticuerpos pd-l1, fragmento de union al antigeno del mismo, y aplicacion medica de ello.
WO2016029073A3 (en) Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
PH12018501153A1 (en) Novel anti-claudin antibodies and methods of use
MA39909A (fr) Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
PH12016502345B1 (en) Anti-gitr antibodies and methods of use thereof
WO2015123423A3 (en) Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
TN2017000072A1 (en) Combination alzheimer therapy using anti-n3pglu abeta antibodies + a bace inhibitor
EP4603508A3 (en) Anti-frizzled antibodies and methods of use
EP3513789A3 (en) Prophylactic and therapeutic agents for fgfr3 diseases
IL274007A (en) Anti-CD3 antibody and a pharmaceutical preparation containing it for the treatment of cancer
WO2018067520A3 (en) Therapeutic agents and methods:
AU2018256669A1 (en) Combination therapy
MX2019009630A (es) Programa de dosificacion de un inhibidor de wnt y una molecula de anticuerpo anti-pd-1 en combinacion.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
EP4311575A3 (en) Methotrexate for proliferative vitreoretinopathy
MY181835A (en) Humanized monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
PH12018500258A1 (en) Antibody
HK1252514A1 (zh) 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂
AU2015278731B2 (en) Fused triterpene compounds and uses thereof
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use